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Background: Macrophages serve as intracellular reservoirs of S. aureus. Recent in vitro studies have confirmed high
level resistance by S. aureus to macrophage mediated killing and the intracellular persistence of Staphylococci may
play an important role in the pathogenesis. Since this localization protects them from both cell-mediated and
humoral immune responses, therefore, a successful anti-staphylococcal therapy should include the elimination of
intracellular bacteria, further protecting the host cells from staphylococci-induced cell death. So, only antibiotic
therapy may not be helpful, successful therapy needs combination of drugs not only for elimination of pathogen
but also for rescuing the host cell for S. aureus induced cell death.
Methods: In keeping with this idea an in vitro study has been done to examine the effect of Riboflavin along with
antibiotics on phagocytosis, hydorgen peroxide, superoxide production, antioxidant enzyme levels, and cytokine levels in
mouse macrophages for amelioration of the Staphylococcus aureus burden. The immune boosting effects of Riboflavin
have been validated through perturbations of redox homeostasis and pro-inflammatory cytokines measurements.
Results: It was observed that the supplementation of Vitamin B-2 (Riboflavin) not only enhances macrophage function as
previously reported but also decreases pro-inflammatory responses in Staphylococcus aureus infected macrophages. The
observed influence of Riboflavin on enhanced antimicrobial effects such as enhanced phagocytosis of macrophages
exposed to S. aureus, hydrogen peroxide or superoxide production when combined with either ciprofloxacin (CIP) or
Azithromycin (AZM) and decrease in pro-inflammatory responses of IFN-γ, IL-6, IL-1β. Riboflavin treatment also decreased
NO and TNF-α level possibly by inhibiting the NF-κβ pathway. The increased antioxidant enzymes like glutathione
reductase, SOD and GSH level helped in maintaining a stable redox state in the cell.
Conclusion: Riboflavin plus antibiotic pretreatment not only enhances macrophage functions but also decreases
proinflammatory responses in Staphylococcus aureus infected macrophages indicating better bacterial clearance and
regulated inflammation which may be considered as a novel and important therapeutic intervention.
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Phagocytic effecter function is the basic to host defense
against intracellular pathogens such as Staphylococcus
aureus (S. aureus), the gram positive coccal bacteria,
the etiological agent of local infections (e.g., wound in-
fection, furuncle and cellulitis) to systemic dissemin-
ation (bacteremia) and finally to metastatic infections
(e.g. endocarditis, osteomyelitis and septic arthritis) [1].
Microbes upon entrance to host body are destined to
engulfment by professional phagocytes such as neutro-
phils, macrophages and dendritic cells. Among few or-
ganisms, S.aureus possess diverse mechanism to avoid
destruction in phagolysosomes [2]. Recent in-vitro studies
revealed greater resistance of S.aureus to killing by macro-
phages [3]. Upon internalization by macrophages, S. aur-
eus is widely assumed to be confined within phagosome
following its maturation and fusion with endosomes and
lysosomes, creates an inhospitable environment for invad-
ing microorganisms, boosting acidification, and augmen-
tation of ROS, and other charged anti-microbial peptides
[4]. S. aureus has evolved a diversified array of antioxidant
tools both enzymatic and non-enzymatic to resist immune
mediated oxidative attack [5].
With the emergence of MRSA (methicillin resistant S.
aureus) strains with reduced susceptibility to vancomycin,
and as there are numerous discrepancies for antibiotics
action, starting from the degree of plasma membrane per-
meability, segregation to diverse compartments, to inacti-
vation by intracellular environment [6]. Thus there is the
need of combinational therapy with efficacious antibiotics
having intracellular bactericidal activity, being harsher to
pathogen and least severe to host cells. Thus, different an-
tibiotics or drugs amalgamation can implement successive
anti staphylococcal mission and further not only reduce
infection but can also aid in protection of host cell from
Staphylococcus aureus infection induced cell death.
Riboflavin (vitamin B-2) is an essential micronutrient
found in a large variety of foods. Vitamin B-2 is necessary
for maintaining proper functioning of the nervous, endo-
crine, cardiovascular and immune systems. Riboflavin is
known to elevate immune functions by activation of macro-
phages, conferring bactericidal action from its spectrum of
actions. Riboflavin participates in numerous diverse internal
redox reactions as a part of metabolism. An inadequate
intake of this vitamin would contribute to difficulties in
intermediary metabolism [7]. Riboflavin kinase (RFK) in cell
converts Riboflavin into flavin mononucleotide (FMN) and
flavin adenine dinucleotide (FAD), which are essential
cofactors of dehydrogenases, reductases, and oxidases
including the phagocytic NADPH oxidase 2 (Nox2) and
participate in wide range of redox reactions [8, 9].
Riboflavin as a proteasome inhibitor quenches inflamma-
tion by reduction of proinflammatory cytokines [10].
Moreover, in-vivo treatment of mice with Riboflavinreduces the mortality of mice with septic shock [11] and
enhances the resistance to bacterial infections [12].
Imbalance between Reactive oxygen species (ROS) and
antioxidant enzymes confers to cytotoxicity, and thus bal-
ance between these two ensures prevention from chronic
diseases [13]. ROS produced by NADPH oxidase (NOX)
envisage its role as defense and signaling molecules related
to innate immunity and various other cellular responses
[14]. In the early innate immune response H2O2 kills bac-
teria through classic ROS respiratory burst. Superoxide
anion does not diffuse across the membranes efficiently
and is rapidly dismuted to H2O2 by superoxide dismutase
(SOD). However, H2O2 can diffuse more freely and causes
direct oxidative damage to many pathogens. NOX-2 de-
rived ROS is the main, but not the only source of oxidative
attack on invading organism [15] and are critical compo-
nents for host defense against bacterial infection [16]. As
the balance in the levels and rates of production of ROS
and NO dictates oxidative versus nitrosative stress, these
differences may be crucial in understanding how immune
responses are regulated in host cells upon treatment with
Riboflavin and antibiotics during S. aureus infection. Cells
contain several anti-oxidant systems to protect themselves
from the injury induced by increased intracellular ROS.
However the effect of antibiotics along with Riboflavin
was not investigated in infection induced oxidative stress
and inflammation in macrophages [17].
Azithromycin (AZM), the macrolide antibiotic has the
potential to accumulate inside the cell and therefore have
an intracellular responsiveness [18]. Intracellular azithromy-
cin enhances phagocytic killing of staphylococci. Azithro-
mycin has the ability to concentrate within neutrophils, and
dynamically act against intracellular organisms [19]. Cipro-
floxacin (CIP) which belongs to group of fluoroquinolones
is potent synthetic agents active against a variety of bacter-
ial species in vitro. Fluroquinolone antibiotics accumulation
in mammalian PMNs can be largely found intracellularly
than extracellularly. Further, it has also been seen that en-
hanced trapping of antibiotic is observed in infected phago-
cytic cell and thus more clearance of bacteria.
Other than antimicrobial activity, antibiotics are also po-
tent immuno-modulators [20]. They are capable of
reducing the production of pro-inflammatory cytokines
like IL-1β, IL-6, IL-8, TNF-α, IFN-γ and also regulate anti-
inflammatory IL-10 in the cytokine milieu during acute
phase inflammatory processes [21, 22]. Furthermore, anti-
biotics diminish the release of various oxidizing species
like superoxide anion and nitric oxide that take part in the
innate immunity of the host phagocytic cells, their
prominent modulatory effect on several nuclear transcrip-
tion factors such as NF-κB and activator protein-1 (AP-1)
in the cell cytosol has been documented. [23].
But as already mentioned, although advancement
antibiotic dosing regimen, the increasing prevalence of
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health problem that has been exacerbated by the dearth of
novel classes of antibiotics. Herein, we tried combination
therapies for the treatment of multidrug-resistant bacterial
infections using an in vitro infection model. These efforts
include antibiotic–antibiotic combinations, such as AZM
and CIP along with the use of certain other agents like
Riboflavin, which could delineate S. aureus burden by acti-
vation of macrophage weaponry against the pathogen by
enhanced production of ROS and cytokines, the therapeutic
approach of which will provide adequate coverage for po-
tential pathogens causing infections.
The present study is a contribution to the current
knowledge about oxidative stress caused by S. aureus in-
fection in macrophages, suggesting that an investigation
of ROS, NO and antioxidant enzymes should be per-
formed in order to detect the contribution of infection
induced oxidative stress and inflammation and its amelior-
ation by treatment of host cells with Riboflavin and antibi-
otics including CIP and AZM. In response to the regulated
production of NO and pro inflammatory cytokines, there
was a rise in the activity of SOD and enzymes of the Gluta-
thione system and decrease in the expression of COX-2,
the enzyme which drives acute inflammation from its on-
set to its resolution was investigated upon combinational
treatment. Production of pro-inflammatory cytokines was
regulated by combined treatment with Riboflavin and anti-
biotics. Thus, this combinational therapy could bestow
protection to the host cell and ultimately restrict S. aureus
infection induced cell death.
Methods
Maintenance of animals
Animals were maintained and experiments were con-
ducted as accredited by the Institutional Animal Ethics
Committee (IAEC), Department of Physiology, Univer-
sity of Calcutta, under the guidance of CPCSEA (PRO-
POSAL NO: IAEC-III/PROPOSAL/BB/02/2013 dated
24.04.2013) Ministry of Environment and Forest, Gov-
ernment of India. Wild type male Swiss albino mice 6–8
weeks old, weighing 20 ± 4 gm was used for the study and
was maintained in quarantine for 1 week. They were ran-
domized into plastic cages with filter bonnets and saw
dust bedding. Mice were fed a normal rodent diet and tap
water ad libitum. Animal holding rooms were maintained
at 21 to 24 °C and 40–60% humidity with a 12-h light dark
cycle. Before surgery mice were anaesthetized with
inhaling anesthetics (ether). Euthanasia was performed by
general anesthesia followed by vital tissue removal using
2–3% ether for induction and 1% for maintenance.
Preparation of bacteria
The Staphylococcus aureus strain AG-789 was obtained
from Apollo Gleneagles Hospital, Calcutta, West Bengal,India. The bacteria were cultured in Muller Hinton broth
(MHB) purchased from Hi-media and were grown over-
night. Freshly prepared culture was centrifuged so as to
collect bacterial cells from mid logarithmic growth phase.
The cell pellets were then re- suspended with sterile 0.9%
PBS and was diluted to reach an optical density (O.D.) of
0.2 at 660 nm with the help of a spectrophotometer. An
O.D. of 0.2 at 660 nm corresponds to 5 × 107 cells/ml
S.aureus and the colony forming unit (CFU) count of the
desired inoculum was confirmed by serial dilution and
culture on blood agar plates [24].
Isolation of murine peritoneal macrophages
Intra peritoneal injection of 4% sterile thioglycolate
broth, 2 ml of volume was administered in mice. After 4
to 5 days, the resulting peritoneal exudate was harvested
by lavage of the peritoneal cavities of mice with endotoxin-
free Hanks’ solution. Peritoneal macrophages were sus-
pended in 0.83% ammonium chloride solution containing
10% (v/v) Tris buffer (pH 7.65) to lyse erythrocytes. The
cells were re-suspended in RPMI 1640 medium supple-
mented with 10% FBS, 100 IU/ml penicillin, and 100 μg/
ml streptomycin, and then were incubated for 1 h at 37 °C
on plastic surface. Non-adherent cells were removed by as-
piration and washing with RPMI 1640 medium before the
addition of S. aureus. The adherent cells of which more
than 95% were found macrophages as determined by light
microscope and were used for in vitro experiments [25].
Assay for quantification of riboflavin inside the
macrophage
Murine Peritoneal macrophages (5×106 cells/ml) were
mixed with S. aureus (5×106 CFU/ml) in a 1:1 cell: bacter-
ium ratio [26] in RPMI-FBS (5%) and incubated at 37 °C
cell culture incubator in presence of antioxidant Riboflavin
(100 μg/mL) and antibiotics AZM or CIP for 60 and 90
mins. Cells were pelleted down by centrifugation and
washed with PBS. Cells were lysed using 0.1% BSA and
absorbance was measured at 440 nm using a UV-Visible
spectrophotometer and was compared with a standard
curve of Riboflavin, then Riboflavin quantity inside the cell
was analyzed.
Assay for intracellular killing
The presence of a large number of S. aureus bacteria in
some cells that had undergone in vitro culture observed
in the bacterial plate count suggests that the bacteria grow
intracellularly. In addition, it has been reported that S. aur-
eus multiplies in the presence of intact macrophages in cell
cultures and would not grow in macrophage-conditioned
media. Therefore, the number of S. aureus bacteria grown
in a petri dish after time-dependent phagocytosis indicates
the number of S. aureus bacteria that have survived inside
the macrophages after ingestion. For this, murine peritoneal
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(5×106 CFU/ml) in a 1:1 cell: bacterium ratio [26] in RPMI-
FBS (5%) and incubated at 37 °C cell culture incubator for
different times in presence or absence of antioxidant Ribo-
flavin (100 μg/mL) and antibiotics Azithromycin (AZM)
and Ciprofloxacin (CIP). Phagocytosis was stopped by add-
ing cold (4 °C) RPMI-1640 and extracellular S. aureus were
removed by washing the suspension in RPMI, note that we
were unable to use antibiotics to kill bacteria present out-
side of macrophages because engulfed bacteria died quickly
during the period necessary for the action of antibiotics.
Centrifugation was performed and cell culture supernatants
were collected and stored for further assay. The pellets
were disrupted in sterile water containing 0.01% bovine
serum albumin (BSA) by vigorously vortexing to release
intracellular bacteria. The lysates containing bacteria were
plated at serial dilutions on mannitol agar plates. The plates
were incubated at 37 °C for a day or two and the number
of colonies was determined [20].
Study of immunofluorescence for engulfment of bacteria
by peritoneal macrophages and their co-localization by
confocal microscopy
The engulfment of S. aureus by murine peritoneal macro-
phages was analyzed by confocal microscopy. The merged
image, where macrophages were in blue and internalized
bacteria was in green indicated that the internalized bac-
teria were brightly fluorescent after engulfment within peri-
toneal macrophages. Macrophages were cultured, and the
cells were re-suspended in RPMI 1640 medium supple-
mented with 10% FBS, 100 IU/ml penicillin, and 100 μg/ml
streptomycin. At 18 h prior to infection, 5×105 cells were
seeded in six-well plates (total volume 3 ml) (Invitrogen).
Macrophages cell nuclei were stained using Nuclear yellow
(Hoechst S769121) (ab13903) at 250 μg/ml dilution for 2 h.
For the FITC staining of S. aureus, bacteria were grown
overnight at 37 °C in MHB broth. Then the bacteria were
diluted with fresh broth and were cultured until mid-
logarithmic phase of growth (OD600 = 0.3). Bacteria were
harvested, washed with PBSE (PBS + 5 mM EDTA) and ad-
justed to 1x109 CFU/ml. Bacterial pellets of 1×109 CFU
were re-suspended in carbonate buffer (pH = 9.0)
containing 100 μg/ml Fluorescein Isothiocyanate (FITC)
isomer I (Abcam, catalog No: ab 145325) for 1 h at room
temperature. Staphylococci were extensively washed with
PBSE.
Prior to infection, cells were washed with growth
medium without antibiotics and kept for 1 h at 37 °C. A
total of 106 to 108 FITC-stained staphylococci were added
per well. Extracellular staphylococci were killed by incuba-
tion of cells with lysostaphin (Sigma) for 7 min at 37 °C.
After the invasion procedure, cells were rinsed with PBS
and fixed for 15 min with 4% para-formaldehyde. Speci-
mens were mounted on microscopy slides in 10% glyceroland visualized in 60× oil immersion lens. Excitation and
emission filter for FITC is 495/519 nm and for Hoechst is
355/495 nm respectively. Images were acquired by using
an Olympus Laser Confocal Scanning Microscope (Spec-
tral type inverted Microscope IX81) and then analyzed by
using Olympus FV1000 viewer software. Co-localization
was accessed by Pearson correlation coefficient [26].
Assay for quantification of hydrogen peroxide (H2O2)
production
Activation of leukocytes by inflammatory stimuli results in
the local release of ROS and induces hydrogen-peroxide
(H2O2) production. Studies in animals support a critical
role for phagocyte oxidative burst in controlling S. aureus
infection. Therefore, the quantification of H2O2 in this ex-
perimental setup was quite relevant.
After time-dependent phagocytosis, cell lysates were
prepared from the pellet. H2O2 assay from the lysate was
performed according to the method as described earlier
with slight modification [25]. Briefly 70 μl of lysate, 20 μl
Horse Raddish peroxidase (HRP) (500 μg/ml), 70 μl of
Phenol red (500 μg/ml) and 40 μl medium were added
in each well of the micro-titer plate and was allowed for
incubation for 2 h at 37 °C. The reaction was stopped by
adding 25 μl of 2 (N) NaOH and the absorbance reading
was taken at 620 nm. Control set received 40 μl of HBSS
in place of supernatant/lysate. A standard curve for H2O2
was plotted and the amount of H2O2 released in the lysate
was evaluated and expressed in μM/106cells.
Assay for quantification of superoxide anion (O2
−)
production
Because intracellular killing is dependent on oxidants, it
was expected that the amount of superoxide anion re-
leased by the host macrophages also contributes to
oxidant-dependent killing of S. aureus. Since superoxide
anion production has been implicated in many physio-
logical and pathological processes, including host innate
immune and inflammatory responses to pathogens, we
were also interested in determining the amount of super-
oxide anion released in this experimental setup. Super-
oxide anion release assay measures the change in colour
of Cytochrome C (cytC), when reduced by O2- released
from the stimulated macrophages. Lysates were incubated
in presence of Cytochrome C (100 μl at 2 mg/ml). The
production of superoxide anion was monitored spectro-
photometrically at 550 nm with reference to the blank.
The amount of superoxide anion production was
calculated by the following formula [25]: Nano moles of
superoxide anion = (mean absorbance at 550 nm× 15.87).
Determination of intracellular ROS by flow cytometry
The choice of a sensitive method for detection of intracel-
lular ROS is very important for detecting the disturbed
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sition and analysis were performed on BD FACS Verse.
The flow cytometer was equipped with an iron laser with
excitation at 488 nm and 15 mW output power. A single
cell suspension was prepared having a density of 105–106
cells/ml and a minimum of 10,000 cells were measured.
Non fluorescent 2,7-dichlorofluorescin diacetate (DCFH-
DA) was commonly employed which upon esterase activ-
ity within the cells converts to DCFH which may react
with several ROS including hydrogen peroxide, hydroxyl
radicals and peroxynitrite and get converted to a fluores-
cent product (DCF). The amount of DCF was propor-
tional to the amount of ROS present inside the cell.
Briefly, 20 mM DCFHDA stock solution made in DMSO
was diluted in the cultured medium from different groups
of macrophages, to yield 20 mM working solution. Then,
the cells were incubated for 60 min in the dark at 37 °C.
Finally, cells were suspended in PBS, and kept on ice for
immediate detection of intracellular ROS generation at
530 nm [27].
Assay for quantification of nitric oxide (NO) production
The amount of NO released by the macrophages was de-
termined by the Griess assay. 50 μl of lysate was incubated
separately in 40 μM Tris (pH = 7.9) containing 40 μM of
the reduced form of β-Nicotinamide Adenine Dinucleotide
Phosphate, 40 μM Flavin Adenine Dinucleotide and 0.05
U/ml nitrate reductase at 37 °C for 15 min. Reduced sam-
ples were incubated with an equal volume of Griess re-
agent consisting of sulphanilamide; 0.25% (w/v) and N-1-
naphthylethylenediamine; 0.025% (w/v), the mixture was
incubated for 10 mins then the absorbance at 550 nm was
measured. The total nitrate/nitrite concentration was de-
termined by comparison to a reduced NaNO3 standard
curve [25].
Assay of catalase enzyme activity
Typically, S. aureus-stimulated leukocytes produce pro-
inflammatory cytokines, which trigger ROS production
in the tissues through NADPH oxidase activation. Thus,
the level of antioxidant enzymes or their activity displays
the intracellular complex mechanisms of the host’s defense.
Therefore, to determine the activity of these antioxidant
enzymes in neutralizing the ROS molecules produced, we
estimated the antioxidant enzyme activity in the super-
natant or cell-free lysate of macrophages after infection in
the presence or absence of Riboflavin or antibiotics.
Catalase activity in the cell free lysate was determined
spectrophotometrically by measuring the decrease in H2O2
concentration at 440 nm. At time zero, 100 μl of the super-
natant or cell free lysate was added separately to 2.89 ml of
potassium phosphate buffer (pH 7.4) taken in a quartz
cuvette. To it 0.1 ml of 300 mM H2O2 was added and
absorbance was taken at 240 nm for 5 min at 1 minintervals. Catalase activity was expressed in terms of
mmole/min mg protein [20].
Assay of superoxide dismutase (SOD) enzyme activity
In addition to blocking phagolysosomal acidification, sub-
sequent treatment of macrophages with antibiotics might
regulate intracellular ROS and can also protect bacteria
from oxidative stress by modulating bacterial superoxide
dismutase (SOD) expression or catalase activity. So esti-
mation of SOD enzyme activity in this experimental setup
was seemed helpful to get an idea of ROS level.100 μl of
the lysate was mixed separately with 1.5 ml of a Tris-
EDTA-HCl buffer (pH 8.5), then 100 μl of 7.2 mmol/L
pyrogallol was added and the reaction mixture was incu-
bated at 25 °C for 10 min. The reaction was terminated by
the addition of 50 μl of 1M HCI and measured at 420 nm.
One unit was determined as the amount of enzyme that
inhibited the oxidation of pyrogallol by 50%. The activity
was expressed as U/mg protein [20].
GSH assay
SOD, catalase enzymes, and glutathione (GSH) are im-
portant scavengers of the superoxide anion and hydro-
gen peroxide. These enzymes prevent the generation of
the hydroxyl radical and protect the cellular constituents
from oxidative damage. SOD rapidly dismutates super-
oxide anion to H2O2, which is further degraded by cata-
lase into water and oxygen. It was demonstrated that a
decrease in the concentration of cellular GSH indicates
oxidative damage due to stress or inflammation. So esti-
mation of GSH level was also rational in this setup. Re-
duced glutathione content (as acid soluble sulfhydryl)
was estimated by its reaction with DTNB (Ellman’s re-
agent) following the method of Sedlac and Lindsey with
some modifications. 0.3 ml of sample was mixed with
0.3 ml 10% TCA followed by vortexing. Then the mix-
ture was centrifuged at 5000 rpm for 10 min at 40 °C.
To 250 μl of the resultant supernatant, 500 μl 0.8M
Tris–HCl was added followed by addition of 25 μl of 5,
5′ - dithiobis-2-nitrobenzoic acid (DTNB). The absorb-
ance was measured at 412 nm using a UV–VIS spectro-
photometer to determine GSH content. The values were
expressed as nmoles of GSH per mg protein [20].
Lipid peroxidation (LPO) assay
Elevation of LPO level was considered as an indicator of
oxidative stress. Lipid peroxidation of the lysates was deter-
mined as Thio- barbituric acid reactive substances (TBARS).
In brief, the lysate was mixed with trichloro acetic acid-
thiobarbituric acid-hydrochloric acid (TBA-TCA-HCl)
reagent and mixed thoroughly and heated for 20 min at
80 °C. The tubes containing the samples were then cooled
to room temperature. The absorbance of the pink chromo-
gen present in the clear supernatant after centrifugation at
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532 nm using a UV-VIS spectrophotometer. Tetraethoxy-
propane was used as standard. The values were expressed
as nmoles of TBARS per mg protein [13].
Assay of glutathione reductase enzyme activity
The glutathione reductase activity was determined fol-
lowing the oxidation of NADPH to NADP+ during the
reduction of oxidized glutathione. The reaction was initi-
ated by the addition of cell lysate in a quartz cuvette con-
taining 1.5 ml reaction mixture of 0.3 mM of NADPH and
3 mM oxidized glutathione in 0.2 M k2HPO4 buffer (pH =
7.5). The decrease in absorbance at 340 nm was followed
for 3 mins on a spectrophotometer and the glutathione re-
ductase activity was calculated using 6.22, the millimolar
extinction coefficient for NADPH at 340 nm. The activity
glutathione reductase enzyme was expressed as nmol
NADPH/min/mg of protein [28].
Tumor necrosis factor alpha (TNF-α), interferon gamma
(IFN-γ), interleukin-6 (IL-6), Interleukin 1 beta (IL1-β),
interleukin-10 (IL-10) and MCP-1 ELISA assays
As high ratio of IL-10 to TNF-α was associated with fatal
outcome in patients with infection, we focused our study on
the production of pro-inflammatory cytokines and an anti-
inflammatory cytokine. Cytokines such as IFN- γ, IL-1β and
IL-6 reportedly play a protective role in host resistance to
facultative intracellularly growing bacteria. IL-10 is a potent
anti-inflammatory cytokine and inhibits the synthesis of pro-
inflammatory cytokines from TH1 cells, which have a sup-
pressive effect on TNF-α, IFN-γ and IL-12 production. Cyto-
kine concentrations from cell culture supernatants were
determined by sandwiched ELISA. For this in vitro study, su-
pernatants from different groups were normalized to the
protein content by Lowry method before the assay and the
levels of four major pro- inflammatory cytokines TNF-α,
IFN-γ, IL-6, IL-1β along with an anti-inflammatory cytokine
IL-10 and chemokine MCP-1 were determined as per manu-
facturer’s guidelines of Ray biotech, Inc, USA in a Bio-Rad
ELISA Reader at 450 nm. The minimum detectable value of
TNF-α was <60 pg/mL, IFN-γ was <5 pg/mL, IL-6 < 2 pg/
mL, IL-10 < 45 pg/mL, IL-1β < 5 pg/ml and MCP-1 was
<3 pg/ml as given in the manual. The reproducibility of cyto-
kine kits are: intra-assay: CV <10%, inter assay: CV <12%.
Western blot analysis for cyclooxygenase-2 (COX-2)
expression
Given its constitutively expressed nature and predominant
role in prostaglandin synthesis during bacterial infection, po-
tential strategies for drug resistant bacteria based on COX
pathways or inhibiting COX-2 is a potential target. These
data might support that combinatorial antibiotic and Ribo-
flavin treatment mediated COX-2 inhibition or strategies
that disrupt prostaglandin signaling pathways as usefuladjunctive therapies in treating persistent and multi-drug re-
sistant infections. Murine macrophages after treatment with
different combinations as described earlier were lysed with
RIPA-NP40 buffer containing 0.5 mM PMSF, 1 mM so-
dium orthovanadate, and 1 mg/mL protein inhibitor cock-
tail (1 mg/mL leupeptin, 1 mg/mL aprotonin, 10 mg/mL
soybean trypsin inhibitor, 1 mg/mL pepstatin) and normal-
ized to the protein content by Lowry method. Samples con-
taining equal amounts of protein in equal volumes of
sample buffer were separated in a denaturing 10% polyacryl-
amide gel and transferred to a 0.1 μm nitrocellulose mem-
brane. Nonspecific binding sites were blocked with Tris-
buffered saline (TBS; 40 mM Tris, pH 7.6, 300 mM NaCl)
containing 5% nonfat dry milk for 1 h at room temperature.
Membrane was then incubated with primary antibody to
COX-2 (1:500 dilution) (catalogue number: orb106537; Bior-
byt Limited, UK). Blots were washed three times in TBST
(TBS with 0.1% Tween 20), incubated for 2 h with appropri-
ate horseradish peroxidase-conjugated secondary antibody,
developed with the Super Signal chemiluminescent substrate
(Thermo Scientific, USA) and exposed to X-Omat BT films
(Kodak). Beta-tubulin was used as loading control to ensure
equal loading of samples throughout the gel [25].
Statistical analysis
Isolated peritoneal macrophages from mice were pooled
together to obtain the requisite amount of macrophages
(5 × 106 cells/ml), and the different parameters were mea-
sured. This was repeated for three times for each param-
eter (e.g., H2O2 production), then the mean value of these
triplicate experiments was taken for calculation. Data was
expressed as mean ± SD. Means were compared between
groups by using analysis of variance (ANOVA). P < 0.05
was considered significant.
Results
Riboflavin intake by S. aureus infected peritoneal
macrophages inside the cell
Prior treatment of mouse peritoneal macrophages with
riboflavin before S. aureus infection showed significantly
more Riboflavin content inside the cell in comparison to
only Riboflavin pretreated macrophages at 60 and 90 mins
post infection (p < 0.05). The Riboflavin content inside the
macrophages were further increased when in addition to
Riboflavin cells were treated with AZM or CIP prior to
S. aureus infection (Table 1).
Effect of Riboflavin and antibiotic treatment either alone
or in combination on phagocytosis of S. aureus by
peritoneal macrophage
The intracellularly viable bacterial count (CFU) was
significantly (p < 0.05) lessened at 30, 60 and 90 min post
infection when the murine peritoneal macrophages were
pre incubated with Riboflavin and compared to the S.
Table 1 Riboflavin concentration inside the macrophages (μg/ml)
Samples Concentrations of riboflavin uptake (μg/ml)
60 min 90 min
CM + RIBO 37.31724 ± .551 38.21379 ± .482
RIBO + SAM 46.48966 ± 1.724a 46.35172 ± 1.655a
RIBO + AZM + SAM 46.48966 ± 1.724a 54.97241 ± .1379b
RIBO + CIP + SAM 52.76552 ± 0.689b 57.31724 ± .413b
Riboflavin concentrations inside the macrophages were estimated from
the cell lysate by spectrophotometric analysis and were expressed in μg/
ml. Results were shown as mean ± SD of three independent experiments
CM + RIBO Riboflavin pre-treated Control macrophage, RIBO + SAM, Riboflavin
pretreated + S. aureus infected macrophages, RIBO + AZM + SAM Riboflavin and
Azithromycin pretreated macrophages infected with S. aureus, RIBO + CIP + SAM
Riboflavin and Ciprofloxacin pretreated macrophages infected with S. aureus
asignificant difference with respect to CM + RIBO
bsignificant difference with respect to Riboflavin (RIBO+SAM)
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The phagocytic activity of peritoneal macrophages were
further increased upon treatment with Riboflavin along
with antibiotics AZM or CIP for 1 h prior to live S. aureus
infection, whereas maximum phagocytic activity or least
CFU was found at 90 mins when S. aureus infected macro-
phages were co-treated with Ciprofloxacin in combination
with Riboflavin and compared to only S. aureus infected
macrophages at p < 0.05 level of significance (Fig. 1).
Study of immune-fluorescence for engulfment of bacteria
by peritoneal macrophages and their co-localization by
confocal microscopy
Bacterial infection experiments or internalization of S.
aureus in the murine peritoneal macrophages in presenceFig. 1 Effect of Riboflavin and antibiotic treatment on the intracellular killing of S
was determined from the lysate after time dependent phagocytosis in presence
number of CFU/ml lysate. Results were presented as mean ± SD of three indepe
difference with respect to SAM; #, significant difference with respect to Riboflavin
significant difference with respect to ciprofloxacin (CIP) or % Significant differenceof Riboflavin and antibiotics were further analyzed by con-
focal microscopic imaging. Results showed engulfment of
S. aureus by murine peritoneal macrophages at 90 mins of
incubation (Fig. 2). From the Pearson’s Co localization co-
efficient it was found that significantly increased engulf-
ment as evident from more co-localized signals when
macrophages were pre-treated with Riboflavin before S.
aureus infection and compared to only S. aureus infected
macrophages (Fig. 2a, d). Co-localized signals were found
to be significantly (p < 0.05) increased when S. aureus in-
fected macrophages were treated with AZM or CIP and
compared to only S. aureus infected macrophage (Fig. 2a,
b, c). Furthermore, significantly (p < 0.05) increased co-
localized signals was also observed when macrophages
were further treated with AZM or CIP along with Ribofla-
vin and compared to SAM and RIBO + SAM groups
(Fig. 2d, e, f ), which corresponds to more engulfment and
lower colony forming unit in phagocytosis assay.
Effect of Riboflavin and antibiotic treatment on S. aureus
infection-induced hydrogen peroxide production by mur-
ine peritoneal macrophages
We tested whether the used antibiotics as well as Ribo-
flavin has any role in hydrogen peroxide production by
peritoneal macrophages during S. aureus infection. Our
results showed (Fig. 3a) that the increase in the amount
of H2O2 released in the lysate by live S. aureus infected
peritoneal macrophages was significant at 60 and, 90 mins
post infection when compared to control macrophage.
When control macrophages were treated with Riboflavin,
a significant increase in H2O2 production at 60 and. aureus infected murine peritoneal macrophages. Intracellular killing assay
or absence of Riboflavin or antibiotics and was expressed in terms of
ndent experiments. &, significant difference with respect to CM; *, significant
(RIBO) plus S. aureus infected macrophages at P< 0.05 level of significance.^ ,
with respect to Azithromycin (AZM) plus S. aureus infected macrophages
Fig. 2 Study of immunofluorescence for engulfment of bacteria by peritoneal macrophages and their co-localization by confocal microscopy. Phagocytosis
analysis was done by confocal microscopy. In Fig. 2 (a1, b1, c1, d1, e1, f1), the merged image of phagocytosis was depicted, where green (FITC) stained bacteria
were phagocytosed by Hoechst stained (Blue) macrophage. Fig. 2(A2, B2, C2, D2, E2, F2) represent signals from co-localized probes. Fig. 2G Pearson’s correlation
coefficients (PCCs) of images of internalized FITC stained S.aureus in Hoechst stained Riboflavin either alone or AZM or CIP pre-treated Macrophage cells. Fig. 2
(A1, A2) represents SAM, Fig. 2 (B1, B2): AZM+SAM, Fig. 2 (C1, C2): CIP + SAM, Fig. 2 (D1, D2) :RIBO+SAM, Fig. 2 (E1, E2): RIBO+AZM+SAM, Fig. 2 (F1, F2): RIBO+
CIP+ SAM. *, represents significant difference with respect to SAM,#, represent significant difference with respect to RIBO+SAM at p<0.05 level of significance
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S. aureus infected macrophages were incubated in
presence of Riboflavin along with Azithromycin or
Ciprofloxacin, a significant (p < 0.05) H2O2 release
was noticed when compared to SAM as well as
RIBO + SAM. However, Ciprofloxacin along with
Riboflavin treated macrophages showed maximal H2O2
production.
Effect of Riboflavin and antibiotic treatment on S. aureus
infection-induced superoxide anion (O2
−) production by
murine peritoneal macrophages
Our results showed (Fig. 3b) significant increase in the
O2
− released in the lysate by live S. aureus infected peri-
toneal macrophages at 60 and 90 mins post infection
when compared to control macrophages. When the con-
trol macrophages were treated with Riboflavin a signifi-
cant increase in O2
− production was found (Table 2).
When S. aureus infected macrophages were incubated in
presence of Riboflavin along with Azithromycin and
Ciprofloxacin, a significant (p < 0.05) increment insuperoxide anion release was noticed when compared to
SAM at 60 mins and RIBO+ SAM groups at 60 and
90mins respectively. Among these Ciprofloxacin along
with Riboflavin treated macrophages showed maximal O2
−
production.
Effect of Riboflavin and antibiotic treatment on S. aureus
infection-induced cellular ROS production by murine peri-
toneal macrophages
From the hydrogen peroxide and super oxide free radical
production, it was observed that treatment of macrophages
with Riboflavin either alone or in combination with AZM
or CIP after S. aureus infection led to significant increase
(p < 0.05) in hydrogen peroxide and super oxide anion pro-
duction, we further determined the intracellular ROS pro-
duction by flow cytometry at 60 and 90 min after infection.
Following the incubation with DCF-DA, it was observed
that the macrophages which were treated with Riboflavin
and exposed to S. aureus (Fig. 4a, b) showed a marked in-
crease (p < 0.05) in ROS production than that of non Ribo-
flavin treated groups. In addition to it, a significant increase
Fig. 3 Effect of Riboflavin and antibiotic treatment on S. aureus infection induced alteration in the H2O2 release and superoxide anion release in
the lysate of murine peritoneal macrophages. The lysate recovered after time dependent phagocytosis in presence or absence of Riboflavin or
antibiotics were used to determine the H2O2 (a) and superoxide anion release (b) and was expressed in terms of μM/106cell and nM/106cells.
Results were presented as mean ± SD of three independent experiments. CM, Control macrophage; SAM, S. aureus infected macrophages; RIBO +
SAM, Riboflavin pretreated + S. aureus infected macrophages; AZM+ SAM, Azithromycin treated S.aureus infected macrophage; CIP + SAM, Ciprofloxacin
treated S.aureus infected macrophage; RIBO + AZM+ SAM, Riboflavin and Azithromycin pretreated macrophages exposed to S. aureus. RIBO + CIP + SAM,
Riboflavin and Ciprofloxacin pretreated macrophages exposed to S. aureus; &, significant difference with respect to CM *, significant difference with
respect to SAM; #, significant difference with respect to Riboflavin(R) plus S. aureus infected macrophages at P< 0.05 level of significance.^, significant
difference with respect to ciprofloxacin (CIP) or % Significant difference with respect to Azithromycin (AZM) plus S. aureus infected macrophages
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(Fig. 4a) and 90 mins (Fig. 4b) when S. aureus infected
peritoneal macrophages were treated with CIP or AZM
along with Riboflavin and compared to only Riboflavin
treated macrophages. Among these the FITC-A median
value was found to be highest when macrophages were
treated with RIBO and CIP before S.aureus infection which
depicts highest ROS production.
Effect of Riboflavin and antibiotic treatment on S. aureus
infection-induced nitric oxide (NO) production by murine
peritoneal macrophages
The amount of NO released in the lysate respectively at
30, 60 and 90 min post S. aureus infection in presence
of Riboflavin alone or in combination of CIP or AZM
were also determined. A significant increase (p < 0.05) inTable 2 Determination of H2O2, Superoxide anion and nitric oxide (
Groups H2O2 (μM/106cell) Superoxide an
30MINS 60MINS 90MINS 30MINS
Control Mφ 0.85 ± 0.05 0.17 ± 0.03 0.24 ± 0.02 1.25 ± 0.004
Control Mφ + RIBO 1.16 ± 0.1a 2.41 ± 0.05a 2.51 ± 0.08 1.7 ± 0.06a
Control Mφ + AZM 0.77 ± 0.01 0.53 ± 0.01a 0.17 ± 0.03 1.16 ± 0.12
Control Mφ + CIP 1.16 ± 0.1a 1.54 ± 0.02a 1.90 ± 0.08a 1.25 ± 0.004
H2O2, superoxide anion and NO were determined from the control macrophages ei
mean ± SD of three independent experiments
CM Control macrophage, CM + RIBO Riboflavin pre-treated Control macrophage, AZM
pretreated control macrophage
asignificant difference with respect to CMNO production in the S. aureus infected macrophages
was found at 30, 60 min and 90 min of phagocytic time
when compared to control macrophages at level of sig-
nifcance. When the S.aureus infected macrophages were
incubated in presence of only Riboflavin a significant re-
duction in the NO production at 30, 60 and 90 min was
recorded (Fig. 5). The amount of NO production was
further reduced significantly (p < 0.05) in presence of
both Azithromycin or Ciprofloxacin when each were co-
treated with Riboflavin at all three time points and com-
pared with RIBO + SAM. Riboflavin treated groups also
showed significant difference in the presence of only an-
tibiotics treated plus infected groups. However, no sig-
nificant difference was noticed when CIP with Riboflavin
treated group were compared to AZM and Riboflavin
treated group (Fig. 5).NO) released from different control sets
ion (nM/106cells) Nitric oxide (mM/106cells)
60MINS 90MINS 30MINS 60MINS 90MINS
0.90 ± 0.002 0.91 ± 0.002 0.69 ± 0.002 0.71 ± 0.001 0.53 ± 0.018
1.96 ± 0.01a 2.31 ± 0.0a 0.530 ± 0.018 0.45 ± 0.00a 0.40 ± 0.001
1.58 ± 0.02a 2.07 ± 0.002a 0.32 ± 0.017a 0.53 ± 0.01 0.77 ± 0.01a
0.96 ± 0.01 2.15 ± 0.02a 0.72 ± 0.002a 0.85 ± .0.05 0.913 ± 0.01a
ther alone or in combination with RIBO, AZM or CIP. Results were shown as
+ CM Azithromycin pretreated control macrophage, CIP + CM Ciprofloxacin
Fig. 4 Effect of Riboflavin and antibiotics AZM and CIP on intracellular ROS production by murine peritoneal macrophages a represents production of
ROS after 60minutes of incubation b represents production of ROS after 90 minutes of incubation. Peritoneal macrophages were treated with Riboflavin
either alone or in combination with AZM or CIP and exposed to S. aureus and were incubated with 20 μM DCHF-DA for 60 min. Fluorescence from
cells was measured by Flow Cytometry. Results were presented as mean ± SD of three independent experiments. *, significant difference with respect
to SAM; #, significant difference with respect to Riboflavin (RIBO) plus S. aureus infected macrophages at P < 0.05 level of significance
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infection-induced alteration in the activity of catalase
enzyme by murine peritoneal macrophages
Bacterial catalase played an important role in the intra-
cellular survival of S. aureus in murine peritoneal mac-
rophages, we became interested to find out whether
there occur any changes in these antioxidant enzyme ac-
tivities after treatment of S. aureus infected macrophages
with riboflavin in presence or absence of antibiotics
AZM and CIP. A marked increase (p < 0.05) in the activ-
ity of catalase enzyme was observed in the cell lysate of
control macrophages at 30, 60 and 90 mins when were
compared to S. aureus infected macrophages. Significant
reduction in the activity of catalase enzyme was found
when infected macrophages were treated with Ribofla-
vin, though only at 90 min. A significant decrease in
catalase enzyme activity (p< 0.05) was observed in the
cell lysate of S. aureus infected macrophages when
treated with AZM or CIP along with riboflavin than thatof only Riboflavin treated but S. aureus infected macro-
phages (Fig. 6a).
Effect of Riboflavin and antibiotic treatment on S. aureus
infection-induced alteration in the activity of superoxide
dismutase (SOD) enzyme by murine peritoneal
macrophages
On the basis of above finding, we further assessed the
SOD enzyme activity that was increased in case of S.
aureus infected macrophages when compared with the
control group. However, when the S.aureus infected
macrophages were incubated in presence of only Ribo-
flavin a significant (p < 0.05) increment in the activity of
SOD enzyme at 30, 60 and 90 min was recorded in
respect to only infected group (Fig. 6b). A significant
increase in the activity of SOD enzyme was noticed at
60 mins when Azithromycin or Ciprofloxacin were
both co-treated with Riboflavin and increase in 90mins
was noticed only at CIP and RIBO treated group when
Fig. 5 Effect of Riboflavin and antibiotic treatment on S. aureus infection induced nitric oxide release in the supernatant and lysate of murine
peritoneal macrophages. The lysate recovered after time dependent phagocytosis in presence or absence of Riboflavin or antibiotics were used
to determine the nitric oxide (NO) release by the Griess assay and were expressed in terms of mM/106cells. Results were presented as mean ± SD
of three independent experiments. &, significant difference with respect to CM *, significant difference with respect to SAM; #, significant
difference with respect to Riboflavin (RIBO) plus S. aureus infected macrophages at P < 0.05 level of significance.^, significant difference with
respect to ciprofloxacin (CIP) or % Significant difference with respect to Azithromycin (AZM) plus S. aureus infected macrophages
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infected macrophages at (p < 0.05) level of significance
(Fig. 6b).
Effect of Riboflavin and antibiotic treatment on S. aureus
infection-induced alteration in the GSH content by murine
peritoneal macrophages
The amount of GSH content in the lysate was estimated.
As shown in the Fig. 6c, a significant decrease (p < 0.05)
in the GSH content of infected macrophages was noticed
when compared to control macrophages. The increase in
the GSH content in the lysate of Riboflavin treated macro-
phages at 30, 60 and 90 min of post infection with S. aur-
eus were found to be significant (p < 0.05) when compared
to the GSH content after time-dependent phagocytosis by
the macrophages received no Riboflavin. However, addition
of Riboflavin along with antibiotics to the peritoneal
macrophages followed by infection of with S. aureus led to
significant increase (p < 0.05) in the GSH content in lysate
at 60 min and 90 min of incubation with CIP and at
90 mins with AZM treated group when compared to that
of GSH level in Riboflavin treated plus S. aureus infected
macrophages (Fig. 6c).
Effect of Riboflavin and antibiotic treatment on S. aureus
infection induced alteration in the LPO level in the lysate
by murine peritoneal macrophages
Amount of LPO content in the lysate of S. aureus
infected macrophages were significantly higher (P <0.05) than that of control sets at 30, and 60 and 90
mins after S. aureus infection. A significant decrease
of LPO level in the lysate of Riboflavin pre-treated
macrophages were observed (P < 0.05) at 30 and
90 mins post-incubation when compared with the
only S.aureus infected macrophages (Fig. 6d).
Macrophages pretreated either with CIP or AZM
alone before S. aureus infection also showed de-
creased LPO content in the lysate in comparison to
the amount of LPO level by the only S. aureus
infected macrophages at 90 mins. Administration of
either CIP or AZM to the Riboflavin pre-treated
macrophages before S. aureus infection showed
significant (p < 0.05) reduction in LPO content at
60 and 90 mins when compared with Riboflavin plus
S. aureus infected macrophages (Fig. 6d). The LPO
content was also significantly (p < 0.05) lowered at all
time points when Riboflavin pretreated macrophages
were incubated with CIP than AZM before S. aureus
infection.Effect of Riboflavin and antibiotics AZM and CIP on the
glutathione reductase activity of S. aureus infected
murine peritoneal macrophages
The activity of glutathione reductase enzyme in the lysate
was estimated. As shown in Table 3, the increase in the ac-
tivity of glutathione reductase enzyme in the lysate at 30,
60 and 90 min post infection with S. aureus from Riboflavin
pre-treated macrophages were found significant (p < 0.05)
Fig. 6 Effect of Riboflavin and antibiotic treatment (AZM and CIP) on S. aureus infection induced alteration on the activity of catalase, SOD enzyme and
GSH, LPO level in the lysate of murine peritoneal macrophages. The lysate was recovered after time-dependent phagocytosis in the presence or absence
of RIBO or antibiotic treatment, as described in the “Methods and materials” section, and were used to determine the catalase (a), SOD enzyme activity
(b), GSH level (c), and LPO content (d) in the supernatant. Catalase enzyme activity was measured in the presence of 15 μmoles of H2O2/mLof phosphate
buffer and is expressed in terms of mmol/min mg protein (a); SOD enzyme activity was expressed in terms of SOD units/mg protein (b); GSH activity was
expressed in terms of μM/mg protein (c); and LPO content was expressed in terms of nmol of thiobarbituric acid-reactive substances (TBARS) (d) Results
were shown as mean ± SD of three independent experiments. CM, Control macrophage; SAM, S. aureus infected macrophages; RIBO + SAM, Riboflavin
pretreated + S. aureus infected macrophages; AZM+ SAM, Azithromycin treated S.aureus infected macrophage; CIP + SAM, Ciprofloxacin treated S.aureus
infected macrophage; RIBO + AZM+ SAM, Riboflavin and Azithromycin pretreated macrophages exposed to S. aureus. RIBO + CIP + SAM, Riboflavin and
Ciprofloxacin pretreated macrophages exposed to S. aureus; &, significant difference with respect to CM *, significant difference with respect to SAM; #,
significant difference with respect to Riboflavin (RIBO) plus S. aureus infected macrophages at P< 0.05 level of significance. ^, significant difference with
respect tociprofloxacin (CIP) or % Significant difference with respect to Azithromycin (AZM) plus S. aureus infected macrophages
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enzyme after time-dependent phagocytosis by macrophages
treated without Riboflavin. However, addition of Riboflavin
along with antibiotics AZM or CIP to the peritoneal
macrophages followed by infection with S. aureus led to
significant increase (p < 0.05) in the activity of glutathione
reductase enzyme in the lysate at 60 and 90 min of CIP
treated macrophages and only in 90 mins in the AZM
treated group when compared to the activity of glutathione
reductase enzyme of Riboflavin treated S. aureus infected
macrophages (Table 3).Effect of Riboflavin and antibiotic treatment on S. aureus
infection-induced TNF- α, IFN-γ, IL-6, IL-1β and IL-10 and
chemokine MCP-1 production by murine peritoneal
macrophages
Cytokine levels showed a significantly (P < 0.05) decreased
level of TNF-α (Fig. 7a), IFN-γ (Fig. 7b), IL-6 (Fig. 7c),
IL-1β (Fig. 7d) in the media (culture supernatant) with the
increase of phagocytic time in the presence of Riboflavin
when compared to the cytokine levels after time–dependent
phagocytosis with Riboflavin non-treated but S. aureus
infected macrophages. Macrophages that were pretreated
Table 3 Glutathione reductase enzyme activity in the cell lysate
Groups Glutathione reductase enzyme activity (nmol NADPH/min/mg of protein)
30 min 60 min 90 min
CM 0.066 ± 0.001 0.009 ± 0.0001 0.034 ± 0.01
SAM 0.113 ± 0.04a 0.263 ± 0.029a 0.355 ± 0.05a
RIBO + SAM 0.432 ± 0.05b 0.435 ± 0.04b 0.749 ± 0.090b
AZM + SAM 0.058 ± 0.005 0.066 ± 0.001b 0.118 ± 0.021b
CIP + SAM 0.035 ± 0.001b 0.423 ± 0.007b 0.073 ± 0.008b
RIBO+ AZM + SAM 0.457 ± 0.09b, c 0.491 ± 0.034b, c 1.023 ± 0.022b, d, c
RIBO+ CIP + SAM 0.265 ± 0.04b, e 0.529 ± 0.021b, d, e 1.561 ± .127b, d, e
The activity of Glutathione reductase enzyme was determined following the oxidation of NADPH to NADP+ during the reduction of oxidized Glutathione and the
results were expressed as nmole NADPH/min/mg of protein. Results were shown as mean ± SD of three independent experiments
CM, Control macrophage, SAM S. aureus infected macrophages, RIBO + SAM Riboflavin pretreated + S. aureus infected macrophages, AZM + SAM Azithromycin
treated S.aureus infected macrophage, CIP + SAM Ciprofloxacin treated S.aureus infected macrophage, RIBO + AZM + SAM Riboflavin and Azithromycin pretreated
macrophages infected with S. aureus, RIBO + CIP + SAM Riboflavin and Ciprofloxacin pretreated macrophages infected with S. aureus
asignificant difference with respect to CM
bsignificant difference with respect to SAM
csignificant difference with respect to ciprofloxacin (CIP)
dsignificant difference with respect to Riboflavin(RIBO) plus S. aureus infected macrophages at P < 0.05 level of significance
eSignificant difference with respect to Azithromycin (AZM) plus S. aureusinfected macrophages
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also showed reduced level of TNF-α, IFN-γ, IL-6, IL-1β in
the supernatant at 60 and 90 mins in comparison to the
amount of these cytokines released by the only S. aureus in-
fected macrophages. These cytokine production was further
decreased significantly (p < 0.05) when in addition to Ribo-
flavin, macrophages were further incubated with AZM or
CIP at 60 and 90 mins compared to only Riboflavin treated
but S. aureus infected peritoneal macrophages. However,
the level of IL- 10 increased significantly in the medium at
60 and 90 min when Riboflavin pretreated macrophages
were incubated with CIP before S. aureus infection in com-
parison to Riboflavin plus S. aureus infected macrophages
(Fig. 7f).
Chemokine MCP1 also showed a significantly (p < 0.05)
marked reduction in its level in presence of Riboflavin
when compared to Riboflavin non treated macrophages at
30, 60 and 90 mins respectively (Fig. 7e). The production
of MCP1 was further reduced significantly (p < 0.05) in
presence of antibiotics AZM or CIP when compared to
only Riboflavin treated but S.aureus infected peritoneal
macrophages (Fig. 7e).
Effect of Riboflavin alone or with antibiotics AZM and CIP
on the expression of COX-2 in peritoneal macrophages of
Swiss albino mice
The expression of the Cox 2 was studied in murine
peritoneal macrophages exposed to S. aureus when
treated with either Riboflavin alone or in combination of
antibiotics AZM or CIP recovered after 90 min of phago-
cytosis to get a wider overview of the Cox2 enzyme which
play a pivotal role in inflammation. Data presented in Fig. 8
showed increased expressions of Cox2 in the peritoneal
macrophages exposed to S. aureus when compared to thecontrol macrophages at p < 0.05 level of significance. No,
detectable band of COX2 was observed when peritoneal
macrophages were treated with Riboflavin either alone or
with AZM or CIP (Fig. 8).
Discussion
The treatment of S. aureus infections has been increas-
ingly problematic due to the high prevalence of multi-
antibiotic-resistant strains, such as methicillin-resistant S.
aureus, [29] and the emergence of vancomycin-resistant S.
aureus strains. As an alternative to traditional antibiotics
in an era of increasing bacterial resistance, new attention
has focused upon development of agents that can effect-
ively disarm the pathogen burden and allow clearance by
the host. The aim of this study was to determine the intra-
cellular anti-staphylococcal activities of antibiotics CIP
and AZM along with the presence of Riboflavin an estab-
lished modulator of macrophage function to boost patho-
gen clearance and enhance longevity of the host cell by
reducing cell death. It has been reported that Riboflavin at
a concentration of more than 25 μg/ml could enhance
macrophage function in-vitro [30]. Our result of recovered
or uptaken Riboflavin concentration after treatment of
macrophage with 100 μg/ml depicts that intake of Ribofla-
vin by macrophages is more than 40 μg/ml (Table 1)
which according to previous reports is more than the
threshold value required for macrophage activation in-
vitro. Riboflavin uptake is enhanced when macrophages
were exposed to S. aureus and this uptake is incubation
time dependent, i.e., 90mins incubation resulted in more
Riboflavin intake than 60mins of incubation time. From
our experiment of Riboflavin concentration inside the cell
we found that the use of antibiotics AZM and CIP further
enhanced Riboflavin concentration (Table 1). It has been
Fig. 7 Levels of cytokines released in the supernatant as determined by ELISA. Levels of tumour necrosis factor-alpha (TNF-α) (a), interferon-gamma
(IFN-γ) (b), IL-6(c), IL-1β (d), MCP1(e) and IL-10 (f) in the supernatants collected after 30, 60 and 90 min of Staphylococcus aureus–infected macrophages
in the presence or absence of Riboflavin or antibiotics were determined by utilizing ELISA according to the manufacturer’s recommendations and were
expressed from triplicate experiments. &, significant difference with respect to CM *, significant difference with respect to SAM; #, significant difference
with respect to Riboflavin(RIBO) plus S. aureus infected macrophages at P < 0.05 level of significance.^ , significant difference with respect to ciprofloxacin
(CIP) or % Significant difference with respect to Azithromycin (AZM) plus S. aureus infected macrophages
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Fig. 8 Effect of Riboflavin and antibiotics (AZM and CIP) on the expression COX2 analyzed by Western blot. The results in this Fig. 8 showed the
expression of COX 2 protein in peritoneal macrophages after infection with S. aureus from a set of triplicate experiments. All the samples were probed with
β-tubulin to show equal protein loading. ‘&’ represents significant difference with respect to CM (Control macrophage) at p< 0.05 level of significance
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quires transport of Riboflavin from the cytosol into mito-
chondria via mitochondrial flavokinase. Because FAD
itself does not traverse membranes, FAD requires degrad-
ation back to Riboflavin [31]. Therefore trafficking of
Riboflavin inside the macrophages could be expected.
From the bacterial CFU count of S. aureus recovered
after phagocytosis by Riboflavin pre-treated murine peri-
toneal macrophages, where, significantly lower number
of bacteria has been found in comparison to Riboflavin
untreated S. aureus infected macrophages, indicating the
immunomodulatory role of Riboflavin and the presence of
antimicrobial property in azithromycin and ciprofloxacin
further aided in the clearance of the pathogen. Confocal
imaging also depicted more engulfment in presence of
Riboflavin alone or with AZM or CIP. Previous results in-
dicated that the phagocytic ability of the macrophages
may be significantly limited in macrophages with Ribofla-
vin deficiency [8]. Therefore, a lower amount of viable
intracellular bacteria directly correlated with increased
engulfment and subsequent intracellular clearance in the
given experimental set up. Taken together Riboflavin
pretreated cells were active enough to kill the bacteria in
presence of antibiotics. Since treatment with antibiotics
and Riboflavin did not exert any toxic effect on macro-
phage and thus has no effect on the viability ofmacrophages therefore, reduced amount of viable intracel-
lular bacteria could not be expected from decreased
amount of extracellular bacteria or from an impaired
phagocytic activity of macrophages due to the treatment
with antibiotics and Riboflavin. However, we have not
tested whether the treatment of antibiotics used and Ribo-
flavin has any effect directly on the growth of S. aureus.
Undoubtedly with the elicitation of macrophages func-
tion in presence of Riboflavin (Table 1), reactive oxygen
species like H2O2 and superoxide anion elevation has
been found which give the ability to macrophages to
destroy ingested cells. Riboflavin deficient macrophages
may exhibit an impaired ability of phagocytosis and kill-
ing of ingested particles [32]. Decreased levels in ROS
were observed when infected macrophages are treated
with antibiotic alone. It has been shown that macrolides
like AZM are able to inhibit the production of ROS from
neutrophils and this is incubation time dependent [33],
which has been suggested to be partly because of the
stabilization of cell membrane. Macrolides attenuate the
membrane-destabilizing effect of bioactive phospholipids,
such as lysophosphatidylcholine, platelet-activating factor
(PAF), and lyso-PAF, and this is accompanied by a dose-
related inhibition of superoxide production. Interference
with phospholipase/phosphatidic acid phosphohydrolase
may also decrease superoxide generation by phagocytes
Fig. 9 Schematic representation of the study. This study suggests a possible mechanism to augment the immunological response on use of
Riboflavin with antibiotics, AZM and CIP, which is achieved by enhanced ROS, ensuring enhancement of pathogen clearance and by the antioxidant
properties of Riboflavin protection of the host cell is ensured, thus helped in maintaining a balanced redox state in the cell. Riboflavin by its proteasome
inhibitory action might down regulates the NF-κβ pathway, thus reducing pro-inflammatory cytokines, nitric oxide and COX2, which on one hand
prevent infection and on other hand lowers inflammatory damage
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− and H2O2, production in
the lysate of macrophage cultures has revealed higher
concentration of these anions in CIP and Riboflavin treated
infected macrophages but lesser in the RIBO and AZM-
treated infected macrophages after incubation. The phago-
cytosis of microorganisms activates oxidase dependent on
adenine dinucleotide phosphatase (NADPH), which in-
duces the production of high levels of superoxide, H2O2 a
process commonly denominated as respiratory burst.
The enzyme Riboflavin Kinase converts Riboflavin to
FMN and FAD. The crucial enzyme for ROS production
i.e. NADPH oxidase enzyme complex depends on FAD
which is one of the NADPH oxidase component [14, 35],
therefore, elevated H2O2 and O2
− production in Riboflavin
pretreated macrophages obtained in this study is also
relevant and supported by earlier studies Fig. 3a, b]. Super-
oxide anion does not diffuse across membrane efficiently
and is rapidly dismuted to H2O2 by SOD. However, H2O2can diffuse more freely and causes direct oxidative damage
to many pathogens. In the early innate immune responses,
H2O2 kills bacteria through classic ROS respiratory burst.
Further elaboration of ROS, the effecter molecules is
documented in the addition of Ciprofloxacin along with
Riboflavin as it stimulates the oxidative burst in monocyte
and macrophages. Azithromycin when combined with
Riboflavin elicits the function of macrophage but lower in
comparison to Riboflavin when combined to Fluroquino-
lone signaling [36]. In our study pre-treatment of
macrophages with antibiotics does not lead to residual
toxic effects on macrophages, and the effects are due to
changes in response to live cells because in our results by
FACS analysis of ROS a significant increase in ROS pro-
duction on addition of antibiotic CIP was documented
which cannot be attributed by dead cells.
Our data suggest that Riboflavin treatment dimin-
ishes the nitric oxide production by mouse peritoneal
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pression of nitric oxide induction and pro-inflammatory cy-
tokines by novel proteasome inhibitors has been studied in
various experimental models as in LPS stimulated RAW
264.7 macrophage [10]. Role of Riboflavin as a naturally oc-
curring proteasome inhibitor has been extracted from lit-
erature according to which Riboflavin is potent inhibitors
of chymotrypsin-like activity of 20S subunit of rabbit
muscle proteasomes and mouse immune proteasome and
its activity depends on protease site LMP7 and other signal-
ing pathways [10].
In our study of thioglycolate elicited murine peritoneal
macrophage which were infected by S. aureus the path-
way by which Riboflavin is suppressing the NO produc-
tion is through increasing cellular levels of PI-κB and
decrease nuclear translocation of NF-κB, further de-
creasing degradation of ubiquinated PI-κB by the prote-
asome, and this inhibition by Riboflavin results in
decreased translocation of NF-κB to the nucleus [10]. It
has been reported that low levels of H2O2 can enhance
NF-kB activity and higher H2O2 inhibited its activity
[37]. The overall effect of NO and ROS on NF-kB activity
follows a biphasic pattern and many of these observations
are cell and mechanism dependent [38]. In addition, lower
NO produced by S. aureus stimulated macrophages (Fig. 5)
can combine lesser with superoxide to diminish the gener-
ation of additional product with enhanced toxicity, such
as peroxynitrite, suggesting protection from more harmful
ROS in presence of Riboflavin at 60 and 90 mins post in-
cubation [39, 40].
It has been suggested that bacteria that has survived
avoiding the host immune response must have to scav-
enge the host derived O2
− and H2O2 by enhancing bac-
terial SOD and catalase enzyme activity. Higher amount
of SOD enzyme activity might have counteracted with
the increased superoxide radical and H2O2, as evidenced
by the increased SOD activity in lysate of macrophages ex-
posed to S. aureus from Riboflavin treated macrophages.
The increased SOD activity (Fig. 6b) in lysate, therefore,
neutralizes the bactericidal activity of host macrophage
derived O2
− by converting it into H2O2, another oxygen
metabolite having potential antimicrobial activities
whereas, decreased catalase activity (Fig. 6a) in the lysate
of macrophages exposed to recovered S. aureus from
Riboflavin treated macrophages suggests enhanced phago-
cytic capacity of the macrophages. Lesser Catalase and
more SOD enzyme activity has also been documented
when in addition to Riboflavin, cells were further co-
treated with Ciprofloxacin at 60 and 90 mins of incuba-
tion. Macrolide antibiotics like AZM are also known to
alter the physiological redox homeostasis leading to oxida-
tive stress and lipid peroxidation [41]. This induction of
oxidative stress may further reduce the catalase activity in
60 and 90 mins post incubation in presence of Riboflavin(Fig. 3a). Reports also suggests that in acute infection i.e.,
for 60 and 90 mins Ciprofloxacin increases the SOD activ-
ity leading to more production of H2O2 from more gener-
ated superoxide anion [42]. A study investigated the effect
of Riboflavin therapy on diabetic cardiomyopathy docu-
mented that Riboflavin can increase SOD activity in the
heart tissue [43]. So, increase in SOD activity in all Ribofla-
vin treated groups can be attributed to antioxidant prop-
erty of Riboflavin. Earlier it was demonstrated that TNF-α
mediated activation of NF-κB Pathway may be inhibited
by transient over expression of cytosolic SOD1 or mito-
chondrial SOD 2 but not catalase [44].
Glutathione is the master component of the antioxidant
defenses in the cell. Both cellular activities of glutathione
reductase and concentration of reduced glutathione are
markers of flavin status and FMN and FAD participate in a
range of redox reactions including the Glutathione system
Our results demonstrate an increase in both Glutathione
and Glutathione reductase activity when macrophages
were stimulated in presence of Riboflavin at 60 and 90
mins of incubation. Presence of Riboflavin at a dose of
100 μg/ml converted it to FAD which may acted as a co-
enzyme to increase glutathione reductase activity at 60
and 90 mins of incubation in the cell lysate [Table 3]. Fur-
ther activation of glutathione reductase might have in-
creased the reduced glutathione content in the cell as
evident from our study at 60 and 90 mins of incubation
(Fig. 6c) [45]. FAD transports hydrogen from NADPH to
oxidised glutathione to convert it into the reduced form
[46]. Reduced glutathione acts as an endogenous antioxi-
dant in different cell types function of which can be en-
hanced by the activity of Riboflavin.
Increase of GSH and decrease of LPO in Riboflavin
treated groups can be indicators of reduction of oxidative
stress, as lipid peroxidation is a potent agent for cellular
damage which acts by inhibiting membrane enzymes and
receptors, depreciation of LPO and augmentation of GSH
is more prominent when Riboflavin is combined with
AZM/CIP (Fig. 6c and d).
The defense of an organism depends on the recognition
of harmful stimuli followed by appropriate activation of
innate and adaptive immune responses, leading to cytokine
production. Several cytokines have pro-inflammatory actions
that drive the innate immune response, cause inflammation
and activate adaptive immune responses. During infection
and sepsis elevated levels of pro-inflammatory cytokines,
e.g. TNF-α and IFN- γ have been reported [47]. Pro-
inflammatory cytokines like TNF-α, IL-1β, and IL-6 are
inducer of systemic inflammation [20] and can be
detrimental to host cell inducing hemodynamic shock and
cell death. Our research has focused primarily on
macrophages because they are highly sensitive to Riboflavin
stimulation and respond by reducing production of TNF-α,
IL-1β, IL-6 and IFN-γ.
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that belongs to the tumor necrosis factor (TNF) super
family [48]. Increased TNF-α from the Riboflavin plus CIP
or Riboflavin plus AZM treated macrophages at early in-
fection (at 30 min) indicating bacterial killing and better
efficacy of both this antibiotics in presence Riboflavin
(Fig. 7a). However, suppression of TNF-α level at late stage
of infection by both the antibiotics in presence of Ribofla-
vin indicates the combination to be effective in down
regulating inflammation with increasing time which was
beneficial to the host cell. Suppression of IL-1β, IFN-γ as
well as IL-6 (Fig. 7d, b and c) by the Riboflavin and CIP or
AZM treated macrophages at late stage of infection fur-
ther confirms their anti-inflammatory nature. Macrolide
antibiotics reportedly repress the production of pro-
inflammatory cytokines in macrophages [49]. Apart from
the microbicidal activity of fluroquinolone Ciprofloxacin,
reports also pictures CIP also a potent immunomodula-
tory agent [50]. As already discussed Riboflavin is a potent
protease inhibitor and this inhibitory effect governs the
TNF-α signaling pathway through NF-κβ. Classical NF-κβ
consist of heterodimers of p65 and p50 and these are the
potent activators of plethora of general proinflammatory
cytokines such as IL-6, TNF-α etc. In an inactive cell p50/
65, is maintained in the inactive state in the cytoplasm of
cells when it is bound to I-κB. Riboflavin has the capacity
to inhibit proteasome activity in conjunction with their
capacity to increase cellular levels of PI-κB and decrease
nuclear translocation of NF-κB, suggests that the mechan-
ism by which these agents suppress production of TNF-α
and NO, involves decreased degradation of ubiquinated P-
IκB by the proteasome, resulting in depressed transloca-
tion of NF-κB to the nucleus. Thus, Riboflavin exerts is
anti-inflammatory effects by inhibiting NF-κB activation
[10]. Based on these reports, the capacity to increase cellu-
lar levels of P-IκB and subsequently decrease nuclear
translocation of NF-κB, we hypothesized that Riboflavin
possibly down-regulate the NF-κB pathway. Given the
important role of TNF-α in sepsis such suppression by
combination therapy could be a therapeutic effect [51]. It
is also known that exposure of staphylococci to beta-
lactam antibiotics greatly enhances the release of bacterial
cell wall fragments that have strong proinflammatory
properties, such as peptidoglycan and lipoteichoic acid
[52, 53], resulting in the induction of higher TNF-α levels
from monocytes [54]. Previous reports demonstrated the
clinical benefits of antibiotic and TNF-α inhibitor combin-
ation therapies relating to both arthritis severity and bone
destruction in addition to reductions in the mortality rate
by a combination therapy in experimental S. aureus–
induced septic arthritis [55]. Recently we have observed
that certain interaction exists between TNF-α and MMP-
2 during the course of septic arthritis in S. aureus infected
mice, hence further experiments are warranted to figureout the impact of TNF-α on MMP-2 activation via recep-
tors for TNF-α (TNFR-I and TNFR-II) during S. aureus
induced septic arthritis [56].
Among the pro-inflammatory cytokine milieu, anti-
inflammatory cytokine IL-10 was also evaluated and it
was found that early infection in presence of Riboflavin
did not effect this anti-inflammatory cytokine, but at 60
and 90 mins of post incubation IL-10 was found to be
increasing in presence of Riboflavin [57] and this effect
was more prominent in acquaintances of Riboflavin with
AZM and CIP (Fig. 7f ).
Riboflavin is also known to modulate MCP-1 function
which is a potent chemoattractant and a regulatory me-
diator involved in a variety of inflammatory diseases
[58]. Evidences further support the action of fluroquino-
lones and AZM on suppression of MCP1 [59]. Our
report shows a reduction in the value of this chemo-
attractant in Riboflavin treated groups. Further in com-
parison to only Riboflavin treated group, combination
with AZM or CIP further down regulated production of
chemokine MCP 1 (Fig. 7e). Riboflavin action as an in-
flammation regulator has not only been justified but its
role as an anti-inflammatory cytokine enhancer was also
established from this study.
For a clear analysis of inflammation, a well known
hallmark of acute inflammation COX2 expression was
also analysed in our experimental setup [60]. A decrease
in COX2 expression at 90 mins in all Riboflavin treated
group was documented. NO has been found to modulate
PGE2 synthesis in macrophage cell line and rat islet cells
[61]. Our study shows declined production of NO which
might be responsible for reducing COX2 expression as
reduction in expression of iNOS tend to reduce expres-
sion of COX2 modulated by cytokines. IL-1β stimulated
the expression of inducible nitric oxide synthase (iNOS)
by β-cells [62]. So, from our study it can be speculated
that lower level of IL-1β might have reduced the iNOS
synthesis which by similar mechanism reduced COX2
expression. Reduction of inflammatory mediator like
COX2 certainly illustrates Riboflavin as a potent inflam-
mation regulator. In the in-vivo system treatment with
azithromycin and Riboflavin completely eradicated the
bacteria from blood and spleen. TNF-α, IFN-γ, IL-6, and
MCP1 were down regulated by treatment with azithro-
mycin and Riboflavin [63]. Treatment with Riboflavin
also altered the antioxidant status which was further
elaborated by using this combinational therapy in mouse
peritoneal macrophage in the present study.
Caspase-1, however, seems to be uniquely involved in
participating in the inflammatory response by cleaving
the precursors of IL-1 beta, IL-18, and IL-33. Indeed, the
rate-limiting step in inflammation due to IL-1 beta or
IL-18 is the activation of caspase-1 [64]. Recently, a role
for ROS has emerged in the activation of the NLRP3
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caspase-1 and secretion of mature IL-1β [65]. There is a
distinct role for ROS in up-regulation of mRNA for in-
flammatory cytokines such as IL-1β and TNF-α. As,
ROS upregulate Caspase 1 as well as IL-1β, So increase
in ROS production on Riboflavin treatment might have
upregulated Caspase 1 as well as IL-1β in early infections.
In late infections reduction in IL-1β might have reduced
Caspase 1 expression as there are reports that IL-1β secre-
tion and reactive oxygen species (ROS) down-modulate
IL-1β rather than activating it in phagocytes [66].
The isoalloxazine moiety of Riboflavin chelates metals
such as cadmium, cobalt, copper, iron, molybdenum,
manganese, nickel, silver, and zinc [67]. Some bound
metals are easily oxidized and reduced and play a role
in the formation of free radicals. Our study also evi-
denced an enhanced free radical production behind
which iron chelation by Riboflavin may play a signifi-
cant role. Iron has important role to play in the disease
manifestation of a pathogen in the macrophage [68].
Pathogens release siderophores which chelate iron
present in the macrophage for their own survival, but
presence of Iron chelators like Riboflavin in the medium
will chelate the iron and make it unavailable to the bac-
teria secreted siderophores, Thus depletion of Iron will
hinder the pathogen’s replication and thus their survival
will be at a stake.
It appears desirable to keep the concentration of pro-
inflammatory products of pathogens in the tissue low
during the whole course of an infection to decline host cell
death. In clinical practice, a favourable outcome depends
on the antibiotic treatment after hospital admission.
Therefore, the reduction of potentially deleterious patho-
gen derived compounds by rapid initiation of an effective
antibiotic therapy along with choosing compounds which
synergistically act with antibiotics to boost the killing
process and further do not release large amounts of
pathogen products is a promising strategy to over -stimu-
late phagocytic cells and decrease tissue injury. It restricts
host cell damage which depicts a protective approach of
Riboflavin along with antibiotics like AZM and CIP.
Similar results were also found in case of bone marrow
derived macrophages (BMDM) when pre-treated with
Riboflavin and exposed to S.aureus. The phagocytic activ-
ity increased with the treatment of riboflavin along with
increased ROS production leading to augmentation in the
killing of pathogen. This comparative analysis of BMDM
to peritoneal macrophages showed similar mechanism of
action, confirms human relevance, or at least efficacy dur-
ing initial infection conditions.
The use of these novel mechanisms can be implemented
in targeted delivery of drugs through targeted drug
carriers like microcapsules, liposomes and micelles etc. in
in-vivo system. In arthritis, a diversity of organisms arepresent in deep infection, the dominant bacteria are Gram
positive pathogens with S. aureus. Established treatments
rely on the controlled release of antibiotics. Therefore, this
targeted drug carrier will selectively and effectively localize
pharmacologically active moiety of Riboflavin and CIP at
pre selected target in therapeutic concentration while lim-
iting its access to non-targeted cells thereby minimizing
toxic effect and maximizing therapeutic index.
Conclusion
In conclusion, our study suggests a possible mechanism to
potentiate the immunological response on use of Riboflavin
along with combinations of antibiotics, by enhanced ROS,
ensuring augmentation of pathogen clearance and by the
antioxidant properties of Riboflavin protection of the host
cell is ensured, thus helped in maintaining a balanced redox
state in the cell. Riboflavin by its proteasome inhibitory ac-
tion might down regulates the NF-κβ pathway, thus redu-
cing pro-inflammatory cytokines, nitric oxide and COX2,
which ensures protection from infection on one hand and
survival benefit of host cells from inflammatory damage on
the other. The balance between the redox reactions and
antioxidant system suggests a strong therapeutic interven-
tion in serious bacterial infections associated with sepsis at
least in our in-vitro system [Fig. 9].
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